Hisamori Kato

No ORCID on file · 4 papers in corpus
diagnostic-accuracy 2024
Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer
Scientific reports ·doi:10.1038/s41598-024-70228-6

Epithelial ovarian cancer (EOC) is widely recognized as the most lethal gynecological malignancy; however, its early-stage detection remains a considerable clinical challenge. To address this, we have introduced a new method, named Comprehe…

case-report 2023
Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling
Diagnostic pathology ·doi:10.1186/s13000-022-01279-4

BACKGROUND: Uterine adenosarcoma is a rare malignant tumor that accounts for 8% of all uterine sarcomas, and less than 0.2% of all uterine malignancies. However, it is frequently misdiagnosed in clinical examinations, including pathological…

diagnostic-accuracy 2021
Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary
International journal of clinical oncology ·doi:10.1007/s10147-021-01914-y

BACKGROUND: Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we exam…

observational 2017
Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer
Oncotarget ·doi:10.18632/oncotarget.21569

OBJECTIVE: Protein disulfide isomerase (PDI) is an oxidoreductase that is overexpressed in several cancers. PDI family members (PDIs) play a role in various diseases including cancer. Select PDIs were reported as useful markers in other can…